Year : 2009 | Volume
: 51 | Issue : 2 | Page : 150--152
Depression and schizophrenia
Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore - 560 029, India
Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore 560 029
|How to cite this article:|
Andrade C. Depression and schizophrenia.Indian J Psychiatry 2009;51:150-152
|How to cite this URL:|
Andrade C. Depression and schizophrenia. Indian J Psychiatry [serial online] 2009 [cited 2019 Sep 21 ];51:150-152
Available from: http://www.indianjpsychiatry.org/text.asp?2009/51/2/150/49458
A) Schizophrenia and bipolar disorder are both associated with an increased risk of weight gain, incident diabetes mellitus, and the metabolic syndrome; at least a part of the risk is mediated by iatrogenic factors such as atypical antipsychotic medication and mood stabilizers. The relationship between depression and diabetes mellitus has also been studied. With this background, mark True or False against each of the following statements:
Depression is associated with an increased risk of incident diabetes mellitus.Diabetes mellitus is associated with an increased risk of incident depression.Depression is associated with superior treatment adherence to antidiabetic measures.In diabetic samples, inactive persons are less likely to be depressed.In diabetic samples, depressed persons are more likely to be inactive.In diabetic samples, long-term glycemic control is no different between depressed and nondepressed patients.
B) Just as antidepressant augmentation strategies are employed in antidepressant-refractory depression, so too are antipsychotic augmentation strategies considered in antipsychotic-refractory schizophrenia. Lamotrigine is a broad-spectrum antiepileptic drug which has also demonstrated efficacy in the acute treatment of bipolar depression and in the maintenance therapy of rapid-cycling and nonrapid-cycling bipolar disorder. With this background, mark True or False against each of the following statements:
The rationale for the use of lamotrigine in schizophrenia is that the drug is a partial agonist at dopamine autoreceptors.Lamotrigine augmentation of antipsychotic medication attenuates positive symptoms of schizophrenia.Conventional doses of lamotrigine are associated with clinically significant increases in antipsychotic drug levels.There is weak clinical evidence that lamotrigine augmentation may attenuate obsessive-compulsive disorder symptoms in patients with schizophrenia.
A) Depression and diabetes mellitus
Answers: 1. True; 2. True; 3. False. 4. False; 5. True. 6. False.
Mezuk et al.  described a systematic review and meta-analysis of the relationship between depression and Type 2 diabetes. They identified 13 prospective studies of depression which excluded diabetes at baseline, and 7 prospective studies of diabetes which excluded depression at baseline. They found that depression was associated with a 60% increased risk of new-onset diabetes (Relative Risk [RR], 1.60; 95% confidence intervals [CI], 1.37-1.88) and diabetes was associated with a 15% increased risk of new-onset depression (RR, 1.15; 95% CI, 1.02-1.30).
Gonzalez et al.  described a systematic review and meta-analysis of the relationship between depression and treatment nonadherence in 47 studies of patients with type 1 and type 2 diabetes mellitus. They found that depression was significantly associated with treatment nonadherence; studies with better methodology demonstrated larger nonadherence effects.
Lysy et al.  described a systematic review of the relationship between physical activity and depressed mood in Type 2 diabetes patients. They identified 10 cross-sectional studies and 2 trials. They found that, in adults with Type 2 diabetes, inactive persons were 1.72-1.75 times more likely to be depressed, and depressed persons were 1.22-1.90 times more likely to be inactive.
Richardson et al .  examined the longitudinal effects of ICD-9 depression on glycemic control in 11,525 persons with Type 2 diabetes. The mean age of the sample was about 66 years. The sample was 97% male. The sample was followed up for a mean of 4.1 years. Depression was recorded in 6% of the sample. HbA1c values were found to be slightly (by a mean of 0.13%) but significantly higher in depressed persons at all time points during the study.
These findings suggest that, in depressed patients who are not diabetic, efforts should be made to modify lifestyle risk factors for diabetes in order to reduce the risk of future diabetes; and these patients should be monitored so that diabetes, if incident, is detected early. Likewise, diabetic patients should be screened for depression; and if they are not depressed, they should be monitored for incident depression. Finally, in depressed patients who are diabetic, efforts should be made to improve medication adherence and levels of physical activity so that short- and long-term glycemic control is improved.
B) Lamotrigine augmentation in antipsychotic-refractory schizophrenia
Answers: 1. False; 2. False; 3. False; 4. True.
Lamotrigine has no action on dopamine receptors; however, as glutamatergic mechanisms have been proposed to explain schizophrenic symptoms  and as lamotrigine modulates glutamatergic neurotransmission, many studies have examined whether the addition of lamotrigine to an antipsychotic regime improves outcomes in antipsychotic-refractory schizophrenic patients.
In a double-blind, placebo-controlled, 14-week crossover trial, Tiihonen et al .  found that treatment-resistant schizophrenic inpatients (n=34) with clozapine-refractory psychotic symptoms showed small (6-7%) but statistically significant attenuation of positive (but not negative) symptom and general psychopathology ratings with lamotrigine (200 mg/day) augmentation of clozapine.
Kremer et al .  described a 10-week, randomized, double-blind, placebo-controlled study of lamotrigine (up to 400 mg/day) augmentation of conventional and atypical antipsychotic medication in 38 schizophrenic patients with treatment-resistant psychotic symptoms. An intent-to-treat analysis found that lamotrigine was no better than placebo. However, in the completer sample (n=31) lamotrigine significantly attenuated positive and general psychopathology ratings.
A Cochrane Review conducted in 2006  identified 5 trials (pooled n=537) of lamotrigine in schizophrenia. In these trials, lamotrigine was no better than placebo in response rates and in global response; however, positive symptoms, negative symptoms, and PANSS totals improved more with lamotrigine than with placebo. Cognitive measures differed little between lamotrigine and placebo groups.
Zoccali et al .  described a 24-week, randomized, double-blind, placebo-controlled study of lamotrigine (up to 200 mg/day) augmentation of a stable dose of clozapine (150-650 mg/day) in 60 patients with antipsychotic- and clozapine-resistant schizophrenia. In a completer (n=51) analysis, lamotrigine attenuated positive, negative, and general psychopathology symptoms as well as improved certain aspects of cognitive functioning without impacting on clozapine blood levels. One lamotrigine patient dropped out due to rash; otherwise, the medication was well tolerated.
Poyurovsky et al .  described an 8-week uncontrolled trial of lamotrigine (200 mg/day) augmentation in patients with schizophrenia (n=5) or schizoaffective disorder (n=6) and comorbid OCD. In the 9 patients who completed the study, Y-BOCS scores showed a small but statistically significant decline from a mean of 23 at baseline to a mean of 17 at treatment endpoint. Five patients (45%), all schizoaffective, showed at least 35% attenuation of Y-BOCS ratings. Schizophrenic symptomatology did not alter with lamotrigine.
These modestly encouraging studies notwithstanding, two large, well-conducted, randomized, double-blind, placebo-controlled trials (the gold standard in research) yielded negative outcomes. These trials were described by Goff et al .  Both studies were 12 weeks in duration and examined flexibly dosed lamotrigine (100-400 mg/day) augmentation in schizophrenic patients with stable, residual psychotic symptoms that had not responded to atypical antipsychotic medication. In the first study (n=217), negative symptoms and CGI-I ratings unexpectedly improved more with placebo than with lamotrigine. In the second study (n=212), a cognitive composite score improved more with lamotrigine than with placebo. In neither study did lamotrigine outperform placebo on positive symptom or PANSS total scores. Dropout rates were similar in lamotrigine and placebo groups.
Of modest concern are the reports that lamotrigine may rarely worsen psychosis. For example, Brandt et al .  reported that 6 out of about 1400 epileptic patients developed a psychotic disorder during treatment with lamotrigine. Chan et al .  also reported worsening of psychotic symptoms after lamotrigine addition in a patient with schizophrenia. Konstantakopoulos et al .  reported that 3 patients with paranoid schizophrenia experienced worsening of psychotic symptoms within 4-6 weeks of initiation of lamotrigine augmentation; the patients improved within 2 weeks of the withdrawal of lamotrigine. These stray reports could represent a coincidental rather than a cause-effect relationship.
Does lamotrigine alter antipsychotic levels? Bienentreu and Kronmuller  reported that lamotrigine increased risperidone levels in one patient; no mechanism for the interaction appeared evident. However, Spina et al .  found that lamotrigine (up to 200 mg/day) did not alter steady state blood levels of atypical antipsychotic medications or their metabolites in schizophrenic or bipolar patients receiving clozapine (200-500 mg/day), olanzapine (10-20 mg/day), or risperidone (3-6 mg/day); whereas an increase in olanzapine levels was statistically significant, the absolute magnitude of increase was too small to be clinically significant.
What is the take-home message? Many studies with sample sizes in the region of n=50 or less have described improvement in positive symptom and general psychopathology ratings with lamotrigine augmentation of antipsychotic medication in patients with refractory schizophrenic illness. However, two large (n>200, each), randomized, double-blind, placebo-controlled studies found no such benefits. Thus, the usefulness of lamotrigine augmentation in medication-refractory schizophrenia remains to be established. It is theoretically possible that a subgroup of patients may improve, and also that some vulnerable patients may worsen with lamotrigine augmentation. Whether lamotrigine reduces OCD symptoms in schizophrenic patients with comorbid OCD requires formal study. Finally, lamotrigine probably does not influence antipsychotic blood levels; at least, not to a clinically significantly extent.
|1||Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: A meta-analysis. Diabetes Care 2008;31:2383-90.|
|2||Gonzalez JS, Peyrot M, McCarl LA, Collins EM, Serpa L, Mimiaga MJ, et al . Depression and diabetes treatment nonadherence: A meta-analysis. Diabetes Care 2008;31:2398-403.|
|3||Lysy Z, Da Costa D, Dasgupta K. The association of physical activity and depression in Type 2 diabetes. Diabetes Med 2008;25:1133-41.|
|4||Richardson LK, Egede LE, Mueller M, Echols CL, Gebregziabher M. Longitudinal effects of depression on glycemic control in veterans with Type 2 diabetes. Gen Hosp Psychiatry 2008;30:509-14.|
|5||Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367-77.|
|6||Tiihonen J, Hallikainen T, Ryyndnen OP, Repo-Tiihonen E, Kotilainen I, Eronen M, et al . Lamotrigine in treatment-resistant schizophrenia: A randomized placebo-controlled crossover trial. Biol Psychiatry 2003;54:1241-8.|
|7||Kremer I, Vass A, Gorelik I, Bar G, Blanaru M, Javitt DC, et al . Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 2004;56:441-6. |
|8||Premkumar TS, Pick J. Lamotrigine for schizophrenia. Cochrane Database Syst Rev 2006;4:CD005962.|
|9||Zoccali R, Muscatello MR, Bruno A, Cambria R, Micr U, Spina E, et al . The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: A double-blind, placebo-controlled study. Schizophr Res 2007;93:109-16.|
|10||Poyurovsky M, Glick I, Koran L. Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms. J Psychopharmacol 2008 Dec 12. [Epub ahead of print].|
|11||Goff DC, Keefe R, Citrome L, Davy K, Krystal JH, Large C, et al . Lamotrigine as add-on therapy in schizophrenia: Results of 2 placebo-controlled trials. J Clin Psychopharmacol 2007;27:582-9. |
|12||Brandt C, Fueratsch N, Boehme V, Kramme C, Pieridou M, Villagran A, et al . Development of psychosis in patients with epilepsy treated with lamotrigine: Report of six cases and review of the literature. Epilep Behav 2007;11:133-9.|
|13||Chan YC, Miller KM, Shaheen N, Votolato NA, Hankins MB. Worsening of psychotic symptoms in schizophrenia with addition of lamotrigine: A case report. Schizophr Res 2005;78:343-5. |
|14||Konstantakopoulos G, Oulis P, Koulouris GC, Masdrakis VG, Michalopoulou PG. Lamotrigine-associated exacerbation of positive symptoms in paranoid schizophrenia. Schizophr Res 2008;98:325-6. |
|15||Bienentreu SD, Kronmuller KT. Increase in risperidone plasma level with lamotrigine. Am J Psychiatry 2005;162:811-2. |
|16||Spina E, D′Arrigo C, Migliardi G, Santoro V, Muscatello MR, Micr U, et al . Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Ther Drug Monit 2006;28:599-602.|